2022 American Transplant Congress
Safety and Efficacy of GLP-1 Agonists in Solid Organ Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been shown to improve glycemic control, obesity, and cardiovascular disease in the general population. The safety and…2022 American Transplant Congress
Impact of a Pharmacy-Led Post-Transplant Diabetes Mellitus Clinic in Solid Organ Transplant Recipients
*Purpose: To evaluate the impact of a pharmacy-led post-transplant diabetes mellitus (DM) clinic.*Methods: This retrospective chart review from 08/01/20 to 6/30/21 evaluated adult kidney transplant…2022 American Transplant Congress
Is a Single Dose of Steroids in Adult Living Donor Liver Transplant Safe? – A Cohort Analysis
University of California San Francisco, San Francisco, CA
*Purpose: Steroids increase morbidity, and steroid avoidance (SA) has been studied in deceased donor liver transplant but, little is known about SA in living donor…2022 American Transplant Congress
Evaluation of GLP-1 Receptor Agonist Use in the Solid Organ Transplant Population
Pharmacy, University of Colorado Hospital, Aurora, CO
*Purpose: The purpose of this study was to evaluate the utilization of and identify opportunities to optimize the use of glucagon-like peptide-1 receptor agonist (GLP-1…2022 American Transplant Congress
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplant
*Purpose: To evaluate the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RA) in solid organ transplant (SOT).*Methods: This retrospective review included adult kidney, liver,…2022 American Transplant Congress
Safety and Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Solid Organ Transplant Recipients
University Health, San Antonio, TX
*Purpose: To determine the safety and efficacy of sodium glucose cotransporter-2 inhibitors (SGLT2i) in solid organ transplant.*Methods: This is a retrospective review of adult kidney,…2022 American Transplant Congress
Effect of Dual Inhibition of DPP4 and SGLT2 on Tacrolimus-Induced Diabetes Mellitus and Nephrotoxicity in Rat Model
Seoul St.Mary's Hospital, Seoul, Korea, Republic of
*Purpose: Sodium/glucose co-transporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase IV inhibitor (DPP4i) are popular anti-diabetic drugs in type II diabetes mellitus (DM), but their use in…2022 American Transplant Congress
Sodium-Glucose Cotransporter 2 Inhibitors to Treat Diabetes Mellitus After Kidney Transplant
*Purpose: This study describes experience prescribing sodium-glucose cotransport 2 inhibitors (SGLT2i) after kidney transplant to evaluate safety and effectiveness.*Methods: This is a retrospective, institutional review…2022 American Transplant Congress
Diabetes is a Significant and Independent Predictor for Tacrolimus Immediate Release (IR) and LCP-Tacrolimus (LCP) Conversion Ratios
Medical University of South Carolina, Charleston, SC
*Purpose: Diabetes (DM) is a common comorbidity seen in transplant patients with known effects on GI motility and absorption; however, DMs impact on the IR…2022 American Transplant Congress
Safety and Efficacy of SGLT-2 Inhibitors in Solid Organ Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL
*Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been shown to improve glycemic control, blood pressure, cardiovascular mortality, and preserve kidney function in the general population.…
- 1
- 2
- 3
- …
- 7
- Next Page »